Current Neurology and Neuroscience Reports

, Volume 5, Issue 4, pp 284–293

Movement disorder emergencies

  • Steven J. Frucht
Article

Abstract

For the past 4 years, Dr. Stanley Fahn and I have given a course at the American Academy of Neurology annual meeting on the topic of movement disorder emergencies. The purpose of this review article is to summarize the topic and to present it to readers of this journal. The text of this article has appeared in nearly the same form as the Academy syllabus accompanying our course. It is being presented here so that readers of the journal may review the material.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    de Carvalho Aguiar P, Sweadner KJ, et al.: Mutations in the Na+/ K+ -ATPase alpha3 gene ATP1A3 are associated with rapidonset dystonia parkinsonism. Neuron 2004, 43:169–175.PubMedGoogle Scholar
  2. 2.
    Watts R, Koller WC: Movement Disorders. New York: McGraw-Hill; 1997.Google Scholar
  3. 3.
    Bhatt MG, Elias MA, Mankodi AK: Acute and reversible parkinsonism due to organophosphate pesticide intoxication: five cases. Neurology 1999, 52:1467–1471.PubMedGoogle Scholar
  4. 4.
    Ogata A, Tashiro K, Pradhan S: Parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis. Neurology 1999, 53:1781–1786.Google Scholar
  5. 5.
    Rail D, Scholtz C, Swash M: Post-encephalitic parkinsonism: current experience. J Neurol Neurosurg Psychiatry 1981, 44:670–676.PubMedGoogle Scholar
  6. 6.
    Howard RS, Lees AJ: Encephalitis lethargica. A report of four recent cases. Brain 1987, 110:19–33.PubMedGoogle Scholar
  7. 7.
    Blunt SB, Lane RJ, Turjanski N, Perkin GD: Clinical features and management of two cases of encephalitis lethargica. Mov Disord 1997, 12:354–359.PubMedGoogle Scholar
  8. 8.
    Lockman LA, Sung JH, Krivit W: Acute parkinsonian syndrome with demyelinating leukoencephalopathy in bone marrow transplant recipients. Pediatr Neurol 1991, 7:457–463.PubMedGoogle Scholar
  9. 9.
    Mott S, Packer R, Vezina LG, et al.: Encephalopathy with parkinsonian features in children following bone marrow transplantations and high-dose amphotericin-B. Ann Neurol 1995, 37:810–814.PubMedGoogle Scholar
  10. 10.
    Bower JH, Muenter MD: Temporary worsening of parkinsonism in a patient with Parkinson’s disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma. Mov Disord 1995, 10:681–682.PubMedGoogle Scholar
  11. 11.
    Luque FA, Selhorst JB, Petruska P: Parkinsonism induced by high-dose cytosine arabinoside. Mov Disord 1987, 2:219–222.PubMedGoogle Scholar
  12. 12.
    Fleming DR, Mangino PB: Parkinsonian syndrome in a dialysis-supported patient receiving high-dose chemotherapy for multiple myeloma. South Med J 1997, 90:364–365.PubMedGoogle Scholar
  13. 13.
    Boranic M, Raci F: A parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukemia. Biomedicine 1979, 31:124–125.PubMedGoogle Scholar
  14. 14.
    Howell SJL, Sagar HJ: A progressive parkinsonian syndrome developing after chemotherapy and radiotherapy for non-Hodgkin’s lymphoma. Mov Disord 1994, 9:373–374.PubMedGoogle Scholar
  15. 15.
    Oliver L: Parkinsonism due to midbrain compression. Lancet 1959, 2:817–819.PubMedGoogle Scholar
  16. 16.
    De Vera Reyes JA: Parkinsonian-like syndrome caused by posterior fossa tumor. J Neurosurg 1970, 33:599–601.PubMedGoogle Scholar
  17. 17.
    Brazin ME, Epstein LG: Reversible parkinsonism from shunt failure. Pediatr Neurol 1985, 1:306–307.PubMedGoogle Scholar
  18. 18.
    Jankovic J, Newmark M, Peter P: Parkinsonism and acquired hydrocephalus. Mov Disord 1986, 1:59–64.PubMedGoogle Scholar
  19. 19.
    Shahar E, Lambert R, Hwang PA, Hoffman HJ: Obstructive hydrocephalus-induced parkinsonism. I: Decreased basal ganglia regional blood flow. Pediatr Neurol 1988, 4:117–119.PubMedGoogle Scholar
  20. 20.
    Curran T, Lang AE: Parkinsonian syndromes associated with hydrocephalus: case reports, a review of the literature, and pathophysiologic hypotheses. Mov Disord 1994, 9:508–520.PubMedGoogle Scholar
  21. 21.
    Zeidler M, Dorman PJ, Ferguson IT, Bateman DE: Parkinsonism associated with obstructive hydrocephalus due to idiopathic aqueductal stenosis. J Neurol Neurosurg Psychiatry 1998, 64:657–659.PubMedGoogle Scholar
  22. 22.
    Caroff SN, Mann SC: Neuroleptic malignant syndrome. Med Clin North Am 1993, 77:202.Google Scholar
  23. 23.
    Numa A: Neuroleptic malignant syndrome in children. Med J Aust 1991, 155:417–419.PubMedGoogle Scholar
  24. 24.
    Factor SA, Podskalny GD, Barron KD: Persistent neurolepticinduced rigidity and dystonia in AIDS dementia complex: a clinico-pathological case report. J Neurol Sci 1994, 127:114–120.PubMedGoogle Scholar
  25. 25.
    Gabellini AS, Pexxoli A, De Massis P, et al.: Neuroleptic malignant syndrome in an AIDS patient: clinical and pathological findings. Ital J Neurol Sci 1994, 15:293–295.PubMedGoogle Scholar
  26. 26.
    Rodriguez ME, Luquin MR, Lera G, et al.: Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion. Mov Disord 1990, 5:170–172.PubMedGoogle Scholar
  27. 27.
    Addonizio G, Susman VL: ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome. J Clin Psychol 1987, 48:102–105.Google Scholar
  28. 28.
    Friedman JH, Feinberg SS, Feldman RG: A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA 1985, 15:2792–2795.Google Scholar
  29. 29.
    Sechi G, Tanda F, Mutani R: Fatal hyperpyrexia after withdrawal of levodopa. Neurology 1984, 34:249–251.PubMedGoogle Scholar
  30. 30.
    Granner MA, Wooten GF: Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome. Semin Neurol 1991, 11:228–235.PubMedGoogle Scholar
  31. 31.
    Hariz MI, Johansson F: Hardware failure in parkinsonian patients with chronic subthalamic nucleus stimulation is a medical emergency. Mov Disord 2001, 16:166–168.PubMedGoogle Scholar
  32. 32.
    Simpson DM, Davis GC: Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatry 1984, 141:796–797.PubMedGoogle Scholar
  33. 33.
    Mizuta E, Yamasaki S, Nakatake M, Kuno S: Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period. Neurology 1993, 43:1048–1049.PubMedGoogle Scholar
  34. 34.
    Pfeiffer RF, Sucha EL: “On-off”-induced lethal hyperthermia. Mov Disord 1989, 4:338–341.PubMedGoogle Scholar
  35. 35.
    Kuno S, Mizuta E, Yamasaki S: Neuroleptic malignant syndrome in parkinsonian patients: risk factors. Eur Neurol 1997, 38(Suppl):56–59.PubMedGoogle Scholar
  36. 36.
    Sato Y, Asoh T, Metoki N, Satoh K: Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004, 74:574–576.Google Scholar
  37. 37.
    Mann SC, Caroff SN, Bleier HR, et al.: Lethal catatonia. Am J Psychiatry 1986, 143:1374–1381.PubMedGoogle Scholar
  38. 38.
    Hanson DG, Ludlow CL, Bassich CJ: Vocal fold paresis in Shy-Drager syndrome. Ann Otol Rhinol Laryngol 1983, 92:85–90.PubMedGoogle Scholar
  39. 39.
    Martinovits G, Leventon G, Goldhammer Y, Sadeh M: Vocal cord paralysis as a presenting sign in the Shy-Drager syndrome. J Laryng Otol 1988, 102:280–281.Google Scholar
  40. 40.
    Wu T, Chen C, Ro L, et al.: Vocal cord paralysis as an initial sign of multiple system atrophy in the central nervous system. J Formos Med Assoc 1996, 95:804–806.PubMedGoogle Scholar
  41. 41.
    Silber MH, Levine S: Stridor and death in multiple system atrophy. Mov Disord 2000, 15:699–704.PubMedGoogle Scholar
  42. 42.
    Bannister R, Gibson W, Michaels L, Oppenheimer DR: Laryngeal abductor paralysis in multiple system atrophy. Brain 1981, 104:351–368.PubMedGoogle Scholar
  43. 43.
    Isozaki E, Naiot A, Horiguchi S, et al.: Early diagnosis and stage classification of vocal cord abductor paralysis in patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 1996, 60:399–402.PubMedGoogle Scholar
  44. 44.
    Munschauer FE, Loh L, Bannister R, Newsom-Davis J: Abnormal respiration and sudden death during sleep in multiple system atrophy with autonomic failure. Neurology 1990, 40:677–679.PubMedGoogle Scholar
  45. 45.
    Kenyon GS, Apps MC, Traub M: Stridor and obstructive sleep apnea in Shy-Drager syndrome treated by laryngofissure and cord lateralization. Laryngoscope 1984, 94:1106–1108.PubMedGoogle Scholar
  46. 46.
    Iranzo A, Santamaria J, Tolosa E: Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Lancet 2000, 356:1329–1330.PubMedGoogle Scholar
  47. 47.
    Iranzo A, Sntamaria J, Tolosa E, et al.: Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 2004, 63:930–932.PubMedGoogle Scholar
  48. 48.
    Wiest RG, Burgunder JM, Krauss JK: Chronic subdural haematomas and parkinsonian syndromes. Acta Neurochir 1999, 141:753–758.Google Scholar
  49. 49.
    Chou SM, Gutmann L: Deteriorating parkinsonism and subdural hematomas. Neurology 2001, 57:1295.PubMedGoogle Scholar
  50. 50.
    Feve A, Angelard B, Lacau St Guily J: Laryngeal tardive dyskinesia. J Neurol 1995, 242:455–459.PubMedGoogle Scholar
  51. 51.
    Flaherty JA, Lahmeyer HW: Laryngeal-pharyngeal dystonia as a possible cause of asphyxia with haloperidol treatment. Am J Psychiatry 1978, 135:1414–1415.PubMedGoogle Scholar
  52. 52.
    Koek RJ, Pi EH: Acute laryngeal dystonic reactions to neuroleptics. Psychosomatics 1989, 30:359–364.PubMedGoogle Scholar
  53. 53.
    Feve A, Angelard B, Fenelon G, et al.: Postneuroleptic laryngeal dyskinesias: a cause of upper airway obstructive syndrome improved by local injections of botulinum toxin. Mov Disord 1993, 8:217–219.PubMedGoogle Scholar
  54. 54.
    Lew MF, Shindo M, Moskowitz CB, et al.: Adductor laryngeal breathing dystonia in a patient with Lubag (X-linked dystonia-parkinsonism syndrome). Mov Disord 1994, 9:318–320.PubMedGoogle Scholar
  55. 55.
    Marion M, Klap P, Perrin A, Cohen M: Stridor and focal laryngeal dystonia. Lancet 1992, 339:457–458.PubMedGoogle Scholar
  56. 56.
    Jankovic J, Penn AS: Severe dystonia and myoglobinuria. Neurology 1982, 32:1195–1197.PubMedGoogle Scholar
  57. 57.
    Paret G, Tirosh R, Ben-Zeev B, et al.: Rhabdomyolysis due to hereditary torsion dystonia. Pediatr Neurol 1995, 13:83–84.PubMedGoogle Scholar
  58. 58.
    Vaamonde J, Narbona J, Weiser R, et al.: Dystonic storms: a practical management problem. Clin Neuropharmacol 1994, 17:344–347.PubMedGoogle Scholar
  59. 59.
    Manji H, Howard RS, Miller DH, et al.: Status dystonicus: the syndrome and its management. Brain 1998, 121:243–252.PubMedGoogle Scholar
  60. 60.
    Dalvi A, Fahn S, Ford B: Intrathecal baclofen in the treatment of dystonic storm. Mov Disord 1998, 121:611–612.Google Scholar
  61. 61.
    Sacks OW, Kohl M: L-dopa and oculogyric crises. Lancet 1970, 45:215–216.Google Scholar
  62. 62.
    Sachdev P: Tardive and chronically recurrent oculogyric crises. Mov Disord 1993, 8:93–97.PubMedGoogle Scholar
  63. 63.
    FitzGerald PM, Jankovic J: Tardive oculogyric crises. Neurology 1989, 39:1434–1437.PubMedGoogle Scholar
  64. 64.
    Yoshida I, Sakaguchi Y, Matsuishi T, et al.: Acute accidental overdosage of haloperidol in children. Acta Paediatr 1993, 82:877–880.PubMedGoogle Scholar
  65. 65.
    Burke RE, Reches A, Traub MM, et al.: Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985, 17:200–202.PubMedGoogle Scholar
  66. 66.
    Reeves AL, So EL, Sharbrough FW, Krahn LE: Movement disorders associated with the use of gabapentin. Epilepsia 1996, 37:988–990.PubMedGoogle Scholar
  67. 67.
    Shafrir Y, Levy Y, Ben-Amital D, et al.: Oculogyric crisis due to domperidone therapy. Helv Paediat Acta 1985, 40:95.PubMedGoogle Scholar
  68. 68.
    Gorman M, Barkley GL: Oculogyric crisis induced by carbamazepine. Epilepsia 1995, 36:1158–1160.PubMedGoogle Scholar
  69. 69.
    Sacks OW, Kohl M, Schwartz W, Messeloff C: Side-effects of ldopa in postencephalitic parkinsonism. Lancet 1970, 42:1006.Google Scholar
  70. 70.
    Lamberti P, de Mari M, Iliceto G, et al.: Effect of l-dopa on oculogyric crises in a case of dopa-responsive dystonia. Mov Disord 1993, 8:236–237.PubMedGoogle Scholar
  71. 71.
    Kakigi R, Shibasaki H, Katafuchi Y, et al.: The syndrome of bilateral paramedian thalamic infarction associated with oculogyric crisis. Clin Neurol 1986, 26:1100–1105.Google Scholar
  72. 72.
    Heimburger RF: Positional oculogyric crises. J Neurosurg 1988, 69:951–953.PubMedGoogle Scholar
  73. 73.
    Lee MS, Kim YD, Lyoo CH: Oculogyric crisis as an initial manifestation of Wilson’s disease. Neurology 1999, 52:1714–1715.PubMedGoogle Scholar
  74. 74.
    Horiguchi J, Inami Y: Effect of clonazepam on neurolepticinduced oculogyric crisis. Acta Psychiatr Scand 1989, 80:521–523.PubMedGoogle Scholar
  75. 75.
    Hirose G, Kadoya: Cervical spondylotic radiculo-myelopathy in patients with athetoid-dystonic cerebral palsy: clinical evaluation and surgical treatment. J Neurol Neurosurg Psychiatry 1984, 47:775–780.PubMedGoogle Scholar
  76. 76.
    Neng T, Yi C, Xiu-Bao Z, Zhi-Jiao Q: Acute infectious torticollis. Neurology 1983, 33:1344–1346.Google Scholar
  77. 77.
    Berry DS, Moriarty RA: Atlantoaxial subluxation related to pharyngitis: Grisel’s syndrome. Clin Pediatr 1999, 38:673–675.Google Scholar
  78. 78.
    Bredenkamp JK, Maceri DR: Inflammatory torticollis in children. Arch Otolaryngol Head Neck Surg 1990, 116:310–313.PubMedGoogle Scholar
  79. 79.
    Visudhiphan P, Chiemchanya S, Somburanasin R, Dheandhanoo D: Torticollis as the presenting sign in cervical spine infection and tumor. Clin Pediatr 1982, 21:71–76.Google Scholar
  80. 80.
    Shafrir Y, Kaufman BA: Quadriplegia after chiropractic manipulation in an infant with congenital torticollis caused by a spinal cord astrocytoma. J Pediatr 1992, 120:266–269.PubMedGoogle Scholar
  81. 81.
    Subach RB, McLaughlin MR, Albright L, Pollack IF: Current management of pediatric atlantoaxial rotatory subluxation. Spine 1998, 23:2174–2179.PubMedGoogle Scholar
  82. 82.
    Schwarz N: The fate of missed atlanto-axial rotatory subluxation. Arch Orthop Trauma Surg 1998, 117:288–289.PubMedGoogle Scholar
  83. 83.
    Grogaard B, Dullerud R, Magnaes B: Acute torticollis in children due to atlanto-axial rotatory fixation. Arch Orthop Trauma Surg 1993, 112:185–188.PubMedGoogle Scholar
  84. 84.
    Jagoda A, Riggio S, Burguieres T: Cephalic tetanus. Am J Emerg Med 1988, 6:128–130.PubMedGoogle Scholar
  85. 85.
    Dewey RB, Jankovic J: Hemiballism-hemichorea. Arch Neurol 1989, 46:862–867.PubMedGoogle Scholar
  86. 86.
    Yoshikawa M, Yamamoto M, Shibata K, et al.: Hemichorea associated with ipsilateral chronic subdural hematoma. Neurol Med Chir 1992, 32:769–772.Google Scholar
  87. 87.
    Fukui T, Hasegawa Y, Seriyama S, et al.: Hemiballism-hemichorea induced by subcortical ischemia. Can J Neurol Sci 1993, 20:324–328.PubMedGoogle Scholar
  88. 88.
    Lee B, Hwang S, Chang G: Hemiballismus-hemichorea in older diabetic women: a clinical syndrome with MRI correlation. Neurology 1999, 52:646–648.PubMedGoogle Scholar
  89. 89.
    Oerlemans WG, Moll LC: Non-ketotic hyperglycemia in a young woman, presenting as hemiballism-hemichorea. Acta Neurol Scand 1999, 100:411–414.PubMedGoogle Scholar
  90. 90.
    Safirstein B, Shulman L, Weiner WJ: Successful treatment of hemichorea with olanzapine. Mov Disord 1999, 14:532–533.PubMedGoogle Scholar
  91. 91.
    Bashir K, Manyam BV: Clozapine for the control of hemiballismus. Clin Neuropharm 1994, 17:477–480.Google Scholar
  92. 92.
    Harbord MG, Kobayashi JS: Fever producing ballismus in patients with choreoathetosis. J Child Neurol 1991, 6:49–52.PubMedGoogle Scholar
  93. 93.
    Beran-Koehn MA, Zupanc ML, Patterson MC, et al.: Violent recurrent ballism associated with infections in two children with static encephalopathy. Mov Disord 2000, 15:570–574.PubMedGoogle Scholar
  94. 94.
    Krishnamorthy KS, Zalneraitis EL, Young RS, Bernad PG:Phenytoin-induced choreoathetosis in infancy: case reports and a review. Pediatrics 1983, 72:831–834.Google Scholar
  95. 95.
    Okun MS, Jummani RR, Carney PR: Antiphospholipid-associated chorea and ballism in a child with cerebral palsy. Pediatr Neurol 2000, 23:62–63.PubMedGoogle Scholar
  96. 96.
    Faheem AD, Brightwell DR, Burton GC, Struss A: Respiratory dyskinesias and dysarthria from prolonged neuroleptic use: tardive dyskinesia? Am J Psychiatry 1982, 139:517–518.PubMedGoogle Scholar
  97. 97.
    Ahmed S, Chengappa KN, Naidu VR, et al.: Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry 1998, 59:472–477.PubMedGoogle Scholar
  98. 98.
    Samie MR, Dannenhoffer MA, Rozek S: Life-threatening tardive dyskinesia caused by metoclopramide. Mov Disord 1987, 2:125–129.PubMedGoogle Scholar
  99. 99.
    Ovsiew F, Meador KJ, Sethi K: Verapamil for severe hyperkinetic movement disorders. Mov Disord 1998, 13:341–344.PubMedGoogle Scholar
  100. 100.
    Lowe TL, Cohen DJ, Detlor J, et al.: Stimulant medications precipitate Tourette’s syndrome. JAMA 1982, 247:1729–1731.PubMedGoogle Scholar
  101. 101.
    Swedo SE, Leonard HL, Garvey M, et al.: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatr 1998, 155:264–271.PubMedGoogle Scholar
  102. 102.
    Perlmutter SJ, Leitman SF, Garvey MA, et al.: Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999, 354:1153–1158.PubMedGoogle Scholar
  103. 103.
    Goldenberg JN, Brown SB, Weiner WJ: Coprolalia in younger patients with Gilles de la Tourette syndrome. Mov Disord 1994, 9:622–625.PubMedGoogle Scholar
  104. 104.
    Scott BL, Jankovic J, Donovan DT: Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette’s syndrome. Mov Disord 1996, 11:431–433.PubMedGoogle Scholar
  105. 105.
    Salloway S, Stewart CF, Israeli L, et al.: Mov Disord 1996, 11:746–748.PubMedGoogle Scholar
  106. 106.
    Trimble MR, Whurr R, Brookes G, Robertson MM: Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord 1998, 13:617–619.PubMedGoogle Scholar
  107. 107.
    Jankovic J: Botulinum toxin in the treatment of dystonic tics. Mov Disord 1994, 9:347–349.PubMedGoogle Scholar
  108. 108.
    Kwak CH, Hanna PA, Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol 2000, 57:1190–1193. Important study.PubMedGoogle Scholar
  109. 109.
    Goetz CG, Klawans HL: Gilles de la Tourette syndrome and compressive neuropathies. Ann Neurol 1980, 8:453.PubMedGoogle Scholar
  110. 110.
    Brill CB, Hartz WH, Mancall EL: Cervical disc herniation in the Gilles de la Tourette syndrome. Ann Neurol 1981, 9:311.PubMedGoogle Scholar
  111. 111.
    Krauss JK, Jankovic J: Severe motor tics causing cervical myelopathy in Tourette’s syndrome. Mov Disord 1996, 11:563–566.PubMedGoogle Scholar
  112. 112.
    Mills KC: Serotonin syndrome. Am Fam Phys 1995, 52:1475–1482.Google Scholar
  113. 113.
    Mills KC: Serotonin syndrome. Crit Care Clin 1997, 13:763–783.PubMedGoogle Scholar
  114. 114.
    Sternbach H: The serotonin syndrome. Am J Psychiatry 1991, 148:705–713.PubMedGoogle Scholar
  115. 115.
    LoCurto MJ: The serotonin syndrome. Emerg Med Clin North Am 1997, 15:665–675.PubMedGoogle Scholar
  116. 116.
    Graudins A, Stearman A, Chan B: Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998, 16:615–619.PubMedGoogle Scholar
  117. 117.
    Cioni G, Biagionin E, Bottai P, et al.: Hyperekplexia and stiffbaby syndrome: an identical neurological disorder? Ital J Neurol Sci 1993, 14:145–152.PubMedGoogle Scholar
  118. 118.
    Gherpelli JL, Nogueira AR, Troster EJ, et al.: Hyperekplexia, a cause of neonatal apnea: a case report. Brain Development 1995, 17:114–116.PubMedGoogle Scholar
  119. 119.
    Nigro MA, Lim HC: Hyperekplexia and sudden neonatal death. Pediatr Neurol 1992, 8:221–225.PubMedGoogle Scholar
  120. 120.
    Scarcella A, Coppola G: Neonatal sporadic hyperekplexia: a rare and often unrecognized entity. Brain Development 1997, 19:226–228.PubMedGoogle Scholar
  121. 121.
    Kurczynski TW: Hyperekplexia. Arch Neurol 1983, 40:246–248.PubMedGoogle Scholar
  122. 122.
    Shahar E, Brand N, Uziel Y, Barak Y: Nose tapping test inducing a generalized flexor spasm: a hallmark of hyperekplexia. Acta Paediatr Scand 1991, 80:1073–1077.PubMedGoogle Scholar
  123. 123.
    Frucht SJ, Fahn S: A 23-year-old man with arm and vocal tremor. In Clinical Cases in Neurology. Edited by Schapira AH, Rowland LP. Oxford: Butterworth Heinemann; 2001.Google Scholar
  124. 124.
    Denny-Brown D: Diseases of the Basal Ganglia and Subthalamic Nucleus. New York: Oxford Medical Publications; 1946:302.Google Scholar
  125. 125.
    Kong C, Ko C, Tong S, Lam C: Atypical presentation of doparesponsive dystonia: generalized hypotonia and proximal weakness. Neurology 2001, 57:1121–1124.PubMedGoogle Scholar
  126. 126.
    Furukawa Y, Graf WD, Wong H, et al.: Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology 2001, 56:260–263.PubMedGoogle Scholar
  127. 127.
    Anderson M: Neurology of Whipple’s disease. J Neurol Neurosurg Psychiatry 2000, 68:2–5.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Steven J. Frucht
    • 1
  1. 1.Department of NeurologyColumbia University Medical CenterNew YorkUSA

Personalised recommendations